Stockreport

ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Tri...

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF Highest reported pathologic complete response rate seen in a phase 3 registrational trial for HER2 positive early breast cancer with favorable safety profile versus stan [Read more]